干细胞相关共同研究及授权契约:2010年～2025年

本报告全面解读了由世界领先生物製药公司签署的干细胞协议，并提供了前所未有的存取权限。

本报告详细解读并分析了公司签署干细胞协议的方式和原因。这些协议通常涉及多个方面，通常从合作研发开始，直到成果商业化。

报告涵盖了各种类型的合作协议，包括合作研发和授权协议。

本报告提供了自2010年以来已宣布的533项干细胞相关协议的综合列表，并儘可能包含财务条款。此外，报告还提供了每项协议的在线记录链接，方便您参考实际公开的协议。此外，记录中还包含公司和/或合作伙伴向美国证券交易委员会 (SEC) 提交的合约文件（如有）。

主要优势：

• 了解自2010年以来的合约趋势
• 查看干细胞合作与授权协议
• 基准分析：确定交易的市场价值
• 详细的财务条款：预付款、里程碑付款、特许权使用费
• 按公司名称（A-Z）、交易类型和治疗领域排序的交易目录
• 按价值排序的热门交易
• 最活跃的交易撮合者
• 确定每笔交易的资产和条款
• 存取合约文件：深入了解合约结构
• 尽职调查：评估拟议合约条款是否适合您的合作伙伴
• 节省数百小时的研究时间

合约分析可让您对以下内容进行尽职调查：

• 具体授予或选择哪些权利？
• 合约实际上赋予了合作伙伴什么？
• 授予了哪些独家权利？
• 合约的付款结构是怎样的？
• 如何审计销售和付款？
• 合约期间（生效期间）是多久？
• 合约的主要条款是如何界定的？
• 如何处理知识产权 (IPR)，由谁持有？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和成果揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果公司所有权发生变化，合约会怎样？
• 如何约定再授权和分包条款？
• 公司通常会包含哪些 "范本条款" ？
• 根据合约当事人和合约类型，有哪些 "范本条款" ？
• 公司要求哪个司法管辖区作为合约法下的准据法？

目录

摘要整理

第1章 简介

第2章 干细胞契约趋势

• 各年度的干细胞契约数量
• 最活跃的契约缔结企业
• 干细胞契约:各类型契约
• 干细胞契约:各治疗领域
• 干细胞契约:各业界
• 干细胞交易的交易条件

第3章 主要干细胞契约

• 主要干细胞契约:契约各金额

第4章 最活跃的干细胞契约缔结企业

• 最活跃的干细胞契约缔结企业
• 最活跃的干细胞契约缔结企业简介

第5章 干细胞契约的交易名录

• 干细胞契约的交易名录

第6章 干细胞契约:各技术类型

• 契约名录
• 契约名录- 各企业 (A-Z)
• 契约名录- 各类型契约
• 契约名录- 各治疗领域
• 契约类型定义
• 关于Biopharma Research Ltd
• 目前联盟
• 目前契约
• Current Partnering最近的报告标题

Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of stem cell deals from 2010 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter stem cell deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 533 stem cell deals announced since 2010 including financial terms where available including links to online deal records of actual stem cell partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of stem cell dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in stem cell dealmaking since 2010.

Chapter 3 provides an overview of the leading stem cell deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in stem cell dealmaking with a brief summary followed by a comprehensive listing of stem cell deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of stem cell deals signed and announced since Jan 2010, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific stem cell technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in stem cell deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Stem Cell Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2010
• Browse stem cell collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Stem Cell Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of stem cell trends and structure of deals entered into by leading biopharma companies worldwide.

Stem Cell Collaboration and Licensing Deals includes:

• Trends in stem cell dealmaking in the biopharma industry
• Directory of stem cell deal records covering pharmaceutical and biotechnology
• The leading stem cell deals by value
• Most active stem cell licensing dealmakers
• Stem Cell Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in stem cell dealmaking

• 2.1. Introduction
• 2.2. Stem cell deals over the years
• 2.3. Most active stem cell dealmakers
• 2.4. Stem cell deals by deal type
• 2.5. Stem cell deals by therapy area
• 2.6. Stem cell deals by industry sector
• 2.7. Deal terms for stem cell deals
  • 2.7.1 Stem cell deals headline values
  • 2.7.2 Stem cell deal upfront payments
  • 2.7.3 Stem cell deal milestone payments
  • 2.7.4 Stem cell royalty rates

Chapter 3 - Leading stem cell deals

• 3.1. Introduction
• 3.2. Top stem cell deals by value

Chapter 4 - Most active stem cell dealmakers

• 4.1. Introduction
• 4.2. Most active stem cell dealmakers
• 4.3. Most active stem cell deals company profiles

Chapter 5 - Stem cell contracts dealmaking directory

• 5.1. Introduction
• 5.2. Stem cell contracts dealmaking directory

Chapter 6 - Stem cell dealmaking by technology type

• Deal directory
• Deal directory - Stem cell deals by company A-Z
• Deal directory - Stem cell deals by deal type
• Deal directory - Stem cell deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Stem cell deals since 2010
• Figure 2: Active stem cell dealmaking activity - 2010 - 2025
• Figure 3: Stem cell deals by deal type since 2010
• Figure 4: Stem cell deals by therapy area since 2010
• Figure 5: Stem cell deals by industry sector since 2010
• Figure 6: Stem cell deals with a headline value
• Figure 7: Stem cell deals with an upfront value
• Figure 8: Stem cell deals with a milestone value
• Figure 9: Stem cell deals with a royalty rate value
• Figure 10: Top stem cell deals by value since 2010
• Figure 11: Most active stem cell dealmakers 2010 - 2025
• Figure 12: Stem cell deals by technology type since 2010